Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Actinomycin-D vs Methotrexate in Low-risk GTN
NCT04562558Active, not recruiting
- Start
- Sep 2020
- Primary completion
- Nov 2024
- Modality
- DNA Intercalators/Alkylators, Orthosteric Ligands
- Countries
- 1
01
Overview
Randomised, open-label trial in gestational trophoblastic neoplasia (GTN) comparing Methotrexate with Dactinomycin (2 arms). Primary endpoints: Completely remission rate by single-agent at 8 months and Overall completely remission rate at 12 months. Started Sep 2020; status: active, not recruiting.
02
Drugs
actinomycin Dmethotrexate
03
Conditions
gestational trophoblastic neoplasia (GTN)
Beyond the preview
Go deeper on NCT04562558.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04562558.